CurrentCignaPolicy IP0093

Sarecycline (Seysara) tablets - Coverage Policy

Policy defines medical necessity criteria, continuation, authorization duration, and non-covered uses for sarecycline (Seysara) tablets for treatment of moderate to severe acne vulgaris in Cigna-administered health plans. Coverage may vary by specific benefit plan and preferred product requirements apply.

Policy Summary

PayerCigna

PolicySarecycline (Seysara) tablets - Coverage Policy

Policy CodePolicy IP0093

Change TypeNo material change

Effective DateApr 1, 2023

Next Review DateApr 1, 2024

Key ActionDocument age and failure/contraindication/intolerance to both doxycycline and minocycline before requesting coverage; prior authorization is required and sample receipt does not satisfy criteria.

SourceLink

POLICY UPDATE CHANGES

No material clinical/coverage changes.

2Required prior antibiotic trials (doxycycline & minocycline)

9Minimum patient age (years)

12 moAuthorization duration (max)

Coverage Summary

Sarecycline (Seysara) is a tetracycline indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years and older (indication and age threshold).

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Provider Actions & Authorization Requirements

Prior Authorization

Prior authorization required per policy

Coverage is subject to medical necessity review and plan-specific preferred product requirements; documentation must demonstrate age and documented failure/contraindication/intolerance to both doxycycline and minocycline prior to approval.

Documentation Required

Document prior antibiotic trials

Provider must document failure, contraindication, or intolerance to both doxycycline (monohydrate, hyclate or hyclate ER) and minocycline (immediate-release or extended-release).

Denial Risk

Not covered for other indications

Claims for uses other than moderate to severe acne vulgaris in patients meeting criteria (including infections) are considered experimental/investigational and may be denied.

Billing Rule

Sample product

Receipt of sample product does not satisfy criteria requirements for coverage.

Operational notes: Receipt of sample product does not satisfy criteria requirements for coverage. Coverage is subject to medical necessity review and plan-specific preferred product requirements; documentation must demonstrate age and documented failure/contraindication/intolerance to both doxycycline and minocycline prior to approval.

Clinical Evidence & Guidelines

Evidence summary: Phase 3 randomized trials demonstrated efficacy of once-daily sarecycline at 1.5 mg/kg/day for moderate to severe acne.

Guideline recommendations from the American Academy of Dermatology and the Global Alliance advise that systemic antibiotics not be used as monotherapy and should be used in combination with topical therapies and limited to approximately 3-4 months with reevaluation.

Quantitative evidence

Trial dosing (phase 3)1.5 mg/kg/day

Recommended systemic antibiotic duration (guidelines)limit to shortest possible; re-evaluate at 3-4 months

Definitions & Background

Background: Seysara (sarecycline) is a tetracycline indicated for inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. Limitations of use include that efficacy beyond 12 weeks and safety beyond 12 months have not been established, and the agent has not been evaluated for treatment of infections.

Guideline context: Topical retinoids and benzoyl peroxide are cornerstone therapies; systemic antibiotics (including tetracyclines) are recommended for moderate to severe acne but should not be used as monotherapy and should be limited to the shortest possible duration (generally 3-4 months) with re-evaluation.

Term	Definition
Failure
Insufficient clinical response to therapeutic trial of specified agent
Contraindication or intolerance
Documented reason patient cannot receive or tolerate specified agent